Our Buzz Stock of the Day — Hemispherx Biopharma, Inc. (AMEX: HEB) — was up more than 43 percent at 2:15 p.m. EST.
The Philadelphia-based company’s flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(r) and Oragens.
Hemispherx just announced that it received notice of an Annual Report prepared by a director of the National Institute of Infectious Diseases (NIID) to the governing organization of the Japanese Ministry of Health that reported a series of successful preclinical studies in new pandemic vaccines that rely critically on Ampligen, the company’s experimental RNA nucleic acid being developed for globally important immune system disorders.
Hemispherx’s Japanese partner, Biken Corp., recently completed a series of preclinical tests on Ampligen that were necessary to complete a new product registration in Japan.
The Company also recently completed enrollment of a Phase II flu prevention clinic study in Australia.
Shares of HEB are up about 100% over the past 3 months.